Predicting survival in patients with progressive lung disease
Official title: Survival prediction in patients with progressive fibrosing interstitial lung disease
Funded at Massachusetts General Hospital · NIH-11109671 · Data updated 2026-11-12
This study is looking at how advanced imaging and artificial intelligence can help doctors better predict how progressive fibrosing interstitial lung disease (PF-ILD) will affect patients, so they can make more informed treatment decisions and improve care for those living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 15, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $420,000 |
| NIH project number | 5R01HL164697-04 |
| Project ID | NIH-11109671 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with progressive fibrosing interstitial lung disease who are experiencing worsening symptoms and declining lung function.
✕Less likely to help
Patients with stable interstitial lung disease or those not diagnosed with progressive fibrosing interstitial lung disease may not benefit from this research.
What this research studies
This research focuses on patients with progressive fibrosing interstitial lung disease (PF-ILD), a condition that leads to worsening lung function and high mortality. The study aims to develop an accurate prognostic prediction model using advanced imaging techniques and artificial intelligence to better understand individual patient outcomes. By analyzing high-resolution computed tomography (HRCT) images, the researchers hope to create a staging system that can guide treatment decisions and improve patient management. This approach seeks to address the current limitations in predicting disease progression and treatment efficacy.
Why it matters
Potential benefit: If successful, this research could provide patients with more accurate survival predictions, leading to better-informed treatment decisions and improved management of their condition.
How similar studies have gone: Previous research has shown promise in using imaging techniques and artificial intelligence for prognostic predictions in other lung diseases, suggesting potential success for this novel approach in PF-ILD.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Yoshida, Hiroyuki — Massachusetts General Hospital
- Study coordinator: Yoshida, Hiroyuki
Related research
Other NIH-funded projects on the same topics.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.